Loading
companiesCompany
Hummingbird Bioscience
Hummingbird Bioscience is a Singapore biotech that uses computational biology to pick hard-to-reach antibody epitopes; its HER3 antibody HMBD-001 was developed with Cancer Research UK.
Also called: Hummingbird Bioscience Pte Ltd
Overview
Hummingbird Bioscience uses its Rational Antibody Discovery platform to design antibodies against epitopes that block receptor function. HMBD-001 binds the dimerisation interface of HER3 and prevents ligand-dependent and ligand-independent signalling; it entered the clinic with Cancer Research UK in advanced solid tumours including NRG1 fusion-positive cancers. Other programmes include the VISTA antibody HMBD-002 and antibody-drug conjugates.
Headquarters
Singapore, SG
Scorecard
All companies#374of 1244 companies, score 10
- phase 1/2 +1
- targets +4
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 2 targets, 2 registry studies. Formula on the scorecards page.
Type
Founded
2015
Phase 2monoclonal antibody
HMBD-001 is an experimental monoclonal antibody from Hummingbird Bioscience in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, aimed at HER3 and EGFR.
drugs
Phase 2monoclonal antibody